Approaches for a Policy for Science  by Holmes, David R.
Journal of the American College of Cardiology Vol. 59, No. 24, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Approaches for a Policy for Science
David R. Holmes, JR, MD
Rochester, Minnesota
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.061Dr. Lauer (1), writing from his current position in the
Office of the Director, Division of Cardiovascular Sciences,
National Heart, Lung, and Blood Institute, and from his
former positions as Director of Cardiac Clinical Research at
the Cleveland Clinic Foundation, as well as a contributing
editor of the Journal of the American Medical Association,
explores the nexus of science and policy or policy and
science, both of which are and should be closely aligned. He
raises many excellent points and issues to be considered,
some of which I believe his readers could agree on, whereas
other issues, both conceptual and technical, might generate
considerable discussion and perhaps even controversy.
Areas of Agreement
Dr. Lauer concludes with a call to action to work together
to “ensure that our patients benefit from the incredible
power of the scientific method.” Certainly that is a goal that
can be shared by all.
He raises the issue of computed tomography coronary
angiography (CTCA) to frame his article. CTCA has been
quite controversial in terms of its optimal use: the rapid
progression from one generation of the technology to the
next (e.g., 60- vs. 120-slice scans) and which is the most
useful version from a clinical standpoint. There is a paucity
of comparative effectiveness studies, and there are no ran-
domized clinical trials in this area.
There are data from outcomes-based randomized trials of
diagnostic tests outside the cardiovascular arena (e.g., fecal
occult blood test), in which the finding of an abnormal test
result leads in some cases to life-saving procedures, such as
surgery for asymptomatic malignancies.
Difficulty in enrolling patients in randomized clinical
trials is a real, but a multifaceted, problem. The paperwork
associated with such trials is complex, clinicians are busy and
strapped for resources, funding for research coordinators is
often very problematic, institutional review boards some-
times raise questions that are hard to answer, and insurance
companies may not pay for some of the ancillary tests and
follow-up required by randomized clinical trials.
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Against this background of agreement, there are areas of
concern/disagreement.
1. From a technical standpoint, in Dr. Lauer’s paper (1),
the first reference (which sets the tone for subsequent
discussion) in this scientific paper is written by a “health
industry reporter for USA Today.” That seems to be a
rather inauspicious beginning to a very important article
about policy and science, particularly because Dr. Lauer
calls for recommendations of care based on scientific
study, not based on reports from the lay press.
Dr. Lauer questions the scientific database on which the
“vast majority of guideline recommendations are based,” label-
ing them as “inferior evidence.” It is true that there is a dearth
of randomized clinical trials on many important diagnostic and
therapeutic approaches used in cardiovascular disease. In such
a setting, expert opinion or expert guidance documents are
used. In the real world, when there are difficult decisions to be
made and challenging cases to be managed, a team-based
approach of experts focused on the specific patient at hand has
great value. Accordingly, expert consensus guidelines form a
very important part of medical care. (An interesting, somewhat
parallel liberal-arts comment would be that the writers of the
United States Constitution did not have all that much evidence
on which to base the Constitution, and yet it has been a very
good expert consensus document that has stood the test of
time.) Importantly, some areas of clinical care may not be able
to be tested in randomized clinical trials. In the recent past, the
National Institutes of Health has not been in a position to
generously fund such randomized trials, and industry has
declined to do so. This issue is of central importance.
It also must be kept in mind that trials have their own
biases. Limitations related to selection bias for entry into a
trial may negate general conclusions or the ability to
extrapolate the results to the broad range of clinical practice
seen in day-to-day patient care.
Trials are also affected by the fact that technology changes
rapidly, and the results obtained may differ from one
generation of the technology to the next. For example, the
specific technology used in the recently approved transcath-
eter aortic valve replacement procedure for high-risk pa-
tients with aortic stenosis is based on iterations of the device
that will never be seen in the rest of the world because they
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more recent second- and third-generation devices may make
the procedure more effective and safer.
2. The concept of working closely with government agencies
should be straightforward, but the reality is somewhat different,
as witnessed by the multitude of forms that patients must fill
out to fulfill Medicare/Medicaid requirements or the chal-
lenges facing people who would like to participate in a
randomized clinical trial but are unable to do so because their
insurance carriers will not fund ancillary tests.
3. Finally, it is important to remember that some issues can
be well addressed by nonrandomized studies or registries.
For example, the concept of door-to-balloon time, which
has revolutionized the care of patients with acute myo-
cardial infarction, is based on observational experience
and expert consensus and not, as Dr. Lauer suggests,
based on “inferior evidence.”Summary
The most important message from Dr. Lauer is that we
need to move toward the goal of basing policy on science. In
working together, professional societies, clinicians, scien-
tists, and regulatory agencies can accomplish much.
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